Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
Date:10/2/2008

t of cancer through its affinity for a novel target, lactadherin. Lactadherin is an extracellular matrix protein that is released by numerous types of tumor cells, including most breast cancers, ovarian cancers and prostate cancer. Lactadherin has a critical role in promoting the growth of new blood vessels to support tumor growth through the activation of VEGF-mediated angiogenesis. The target lactadherin and Angiolix are supported and protected by granted patents.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
(Date:9/22/2014)... Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced ... at Emory University, presented long-term follow up data on ... cells in the treatment of amyotrophic lateral sclerosis (ALS ... occurred at the Annual Symposium on ALS of the ... on Friday, and was not open to the public, ...
(Date:9/22/2014)... Pa. , Sept. 22, 2014  Olympus, ... innovative solutions for medical and surgical procedures, among ... a deal with Munich -based ... Kick ® Navigation. This agreement applies to ... for cross-disciplinary U.S. sales and all distribution outside ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
(Date:9/22/2014)... surprising new study pulls back the curtain on one ... in payment and income between physicians who perform operations, ... Contrary to perception, the research indicates, the physician payment ... other procedure-performing doctors. , The new findings counter the ... per minute explains why doctors who perform procedures often ...
(Date:9/22/2014)... Norton HealthDay Reporter MONDAY, ... better when newborn intensive care units (NICU) set up private ... new study finds. Researchers at one children,s hospital found ... less distressed when their NICU switched from the traditional "open-bay" ... online Sept. 22 in the journal Pediatrics , add ...
(Date:9/22/2014)... of patients undergoing breast cancer surgery require additional operations ... tissue in the initial operation. However, researchers at Brigham ... they developed that will help surgeons better distinguish cancerous ... for repeat operations. , The study ... in the Proceedings of the National Academy of ...
(Date:9/22/2014)... (September 22, 2014) McMaster scientists have found that ... class of antibiotics. , Although dozens of antibiotics ... how a certain part of bacteria are created, and ... , The discovery is important as there is ... the cures for infections ineffective. The World Health Organization ...
(Date:9/22/2014)... This Flash Report is a top-line view ... the Prostate Cancer market. , Download the flash report ... any launching Prostate Cancer product:, ... crowded market , Understanding stakeholder interactions with ... thought leaders and stakeholders ,Download the white paper ...
Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:The fine line between breast cancer and normal tissues 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2
... engineer has developed a technique which uses plastidial transformation ... (HSA) from tobacco plants. HSA is an intravenous protein ... ,It is mainly used to stabilize blood ... is used for haemorrhages, burns, surgical operations or when ...
... Veterinary schools in sub-Saharan Africa have joined forces ... allow vets to study// for postgraduate degrees while ... Veterinary E-Learning Consortium, launched in early March, will ... full-time degrees, reported the SciDev.net science-for-development network. ...
... Conference (EBCC-5) have called that patients should have speedy access ... Doctors and patient groups said that women in Europe are ... could help prolong their survival and well being. ... are available to women in the United States far more ...
... Quest? cigarettes seems to have lulled smokers into a ... by researchers// at the Transdisciplinary Tobacco Use Research Center ... the study have been published in the journal Psychology ... study, Caryn Lerman, PhD, Associate Director for Cancer Control ...
... revealed that Africa's TB crisis has its origin in HIV/AIDS, ... two million people who die from TB every year, 1.5 ... the African Medical and Research Foundation (AMREF) clinic in the ... to TB were also infected with HIV. According to Nzioka, ...
... According to studies done at the Yale school of medicine, ... we get when we eat certain foodstuffs//, like garlic, mustard ... receptor they ay also underlines the reaction of the body ... vehicle exhaust and byproducts of certain chemo receptor drugs used ...
Cached Medicine News:Health News:Alternate ways to produce HAS from tobacco plants 2
For injecting viscoelastic to all meridians of the anterior chamber and to coat intraocular lenses. 20G x 7.8in (.90 x 22mm)....
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... is the most versatile diagnostic tool in ... solutions for glaucoma, diabetic retinopathy, age-related macular ... RTA is the only system in the ... pole and the optic nerve areas in ...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Medicine Products: